ArticleFrontiers in oncology2022
Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience.
Bruno Fattizzo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papercites it